Key statistics
On Thursday, Arrowhead Pharmaceuticals Inc (A2RR34:SAO) closed at 14.36, 6.77% above its 52-week low of 13.45, set on Sep 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.60 |
---|---|
High | 14.60 |
Low | 14.36 |
Bid | 8.55 |
Offer | -- |
Previous close | 14.08 |
Average volume | 1.05k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Sep 19 2024 10:59 BST.
More ▼
Press releases
- Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
- Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
- Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
- Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
- Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
- Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
More ▼